Literature DB >> 16905132

The antinociceptive effect of salvinorin A in mice.

Trentini F John1, Larry G French, Joseph S Erlichman.   

Abstract

Salvia divinorum is a hallucinogenic plant used by the Mazatec Indians of Mexico for traditional spiritual ceremonies. The active constituent, salvinorin A, induces profound hallucinations, however the biological mechanism for this action is not known. Affinity-binding studies suggest that the biologic activity of salvinorin A involves the kappa-opioid receptor. The purpose of this study was to evaluate the antinociceptive effect of salvinorin A in mice. Salvinorin A and opioid receptor antagonists were administered intrathecally and the tail-flick latencies were used as a measure of antinociception. Salvinorin A increased tail-flick latencies in a dose-dependent manner (13.9-23.1 nmol) compared to control trials. Pretreatment with the kappa-opioid receptor antagonist nor-binaltorphimine attenuated the salvinorin A induced increase in tail-flick latency. In contrast, neither the mu-opioid receptor antagonist beta-funaltrexamine nor delta-opioid receptor antagonist naltrindole significantly affected the antinociceptive response of salvinorin A administration. These data support previous reports that salvinorin A represents a unique non-alkaloidal agonist for the kappa-opioid receptor.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16905132     DOI: 10.1016/j.ejphar.2006.06.077

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  22 in total

Review 1.  Clerodane diterpenes: sources, structures, and biological activities.

Authors:  Rongtao Li; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Nat Prod Rep       Date:  2016-07-18       Impact factor: 13.423

Review 2.  Endogenous opiates and behavior: 2006.

Authors:  Richard J Bodnar
Journal:  Peptides       Date:  2007-09-11       Impact factor: 3.750

3.  The analgesic and anti-inflammatory effects of Salvinorin A analogue β-tetrahydropyran Salvinorin B in mice.

Authors:  K F Paton; N Kumar; R S Crowley; J L Harper; T E Prisinzano; B M Kivell
Journal:  Eur J Pain       Date:  2017-02-03       Impact factor: 3.931

Review 4.  Salvinorin A analogs as probes in opioid pharmacology.

Authors:  Thomas E Prisinzano; Richard B Rothman
Journal:  Chem Rev       Date:  2008-05       Impact factor: 60.622

Review 5.  Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A.

Authors:  Christopher W Cunningham; Richard B Rothman; Thomas E Prisinzano
Journal:  Pharmacol Rev       Date:  2011-03-28       Impact factor: 25.468

Review 6.  Kappa opioids and the modulation of pain.

Authors:  Bronwyn Kivell; Thomas E Prisinzano
Journal:  Psychopharmacology (Berl)       Date:  2010-04-07       Impact factor: 4.530

7.  Herkinorin analogues with differential beta-arrestin-2 interactions.

Authors:  Kevin Tidgewell; Chad E Groer; Wayne W Harding; Anthony Lozama; Matthew Schmidt; Alfred Marquam; Jessica Hiemstra; John S Partilla; Christina M Dersch; Richard B Rothman; Laura M Bohn; Thomas E Prisinzano
Journal:  J Med Chem       Date:  2008-04-02       Impact factor: 7.446

Review 8.  Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects.

Authors:  Kelly F Paton; Diana V Atigari; Sophia Kaska; Thomas Prisinzano; Bronwyn M Kivell
Journal:  J Pharmacol Exp Ther       Date:  2020-09-10       Impact factor: 4.030

9.  Synthetic studies of neoclerodane diterpenes from Salvia divinorum: role of the furan in affinity for opioid receptors.

Authors:  Denise S Simpson; Kimberly M Lovell; Anthony Lozama; Nina Han; Victor W Day; Christina M Dersch; Richard B Rothman; Thomas E Prisinzano
Journal:  Org Biomol Chem       Date:  2009-07-14       Impact factor: 3.876

Review 10.  Natural products as tools for neuroscience: discovery and development of novel agents to treat drug abuse.

Authors:  Thomas E Prisinzano
Journal:  J Nat Prod       Date:  2009-03-27       Impact factor: 4.050

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.